Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study.

Date publication

avril 2022

Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe , Dr GEOFFROIS Lionnel , Pr LANG Hervé , Pr MALOUF Gabriel , Dr TRICARD Thibault , Dr BURGY Mickaël

Tous les auteurs :
Gaillard V, Lhuillier A, Bigot C, Pierard L, Trensz P, Burgy M, Schuster C, Malouf G, Fritsch A, Lang H, Tricard T, Borchiellini D, Geoffrois L, Barthelemy P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35484315

Résumé

Tyrosine kinase inhibitors (TKIs) remain a cornerstone of metastatic kidney cancer (mRCC). Adverse events (AEs) may lead to dose downregulation, and optimal management of AEs is needed to maintain an efficient dose intensity (DI). The aim of our study was to evaluate the impact of an app-based and nurse-led supportive-care program on DI in mRCC patients.

Mots clés

App-based program, Kidney cancer, Nurse-led program, Supportive care program, TKI

Référence

Support Care Cancer. 2022 Apr 29;: